Reta is an investigational triple-agonist peptide designed to target GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This innovative approach aims to improve metabolic health by enhancing insulin secretion, suppressing appetite, and increasing energy expenditure. Reta is being studied for its potential to treat conditions such as type 2 diabetes, obesity, and other metabolic disorders. Early research suggests promising effects on weight loss and glycemic control.
Research-Based Only
